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Abstract Monomeric bovine pancreatic RNase A has been
transformed into a dimeric ribonuclease with antitumor activity
(Di Donato, A., Cafaro, V. and D’Alessio, G. (1994) J. Biol.
Chem. 269, 17394^17396). This was accomplished by replacing
the residues located in the RNase chain at positions 19, 28, 31,
and 32, with proline, leucine, and two cysteine residues,
respectively, i.e. those present at identical positions in the
subunit of bovine seminal RNase, a dimeric RNase of the
pancreatic-type superfamily, endowed with a powerful antitumor
action. However, as an antitumor agent this mutant dimeric
RNase A is not as powerful as seminal RNase. We report here
site-directed mutagenesis experiments which have led to the
identification of two other amino acid residues, glycine 38 and
111, whose substitution in the polypeptide chain of the first
generation dimeric mutant of RNase A, is capable of conferring
to the mutein the full cytotoxic activity characteristic of native
seminal RNase.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Protein engineering techniques, and site-directed mutagene-
sis in particular, are powerful tools for understating the rela-
tionships between the structure and the function of proteins.
We have applied such an approach for investigating the mo-
lecular basis of the antitumor action of bovine seminal RNase
(BS-RNase) [1].
BS-RNase is a dimeric RNase, homologous to pancreatic
RNase A, with more than 80% sequence identity [2]. Two
dimeric structures have been described for BS-RNase [3,4],
which interconvert into each other, so that BS-RNase is an
equilibrium mixture of two quaternary conformations [3] : one
(named MUM) in which the subunits exchange their N-ter-
minal helices, the other (named M = M) in which no exchange
occurs. It should be added that BS-RNase is very active on
double-stranded RNA, whereas most monomeric RNases
have no activity under the same conditions [5].
The exact mechanism of the antitumor action of BS-RNase
is not completely known. It has been determined [6] that the
internalization of the protein by non-malignant cells has no
apparent e¡ect, whereas in malignant cells BS-RNase is found
to degrade ribosomal RNA and inhibit protein synthesis. Fur-
thermore, using a variety of experimental approaches we have
discovered that BS-RNase cytotoxic action depends on its
catalytical activity as a ribonuclease [7], and on its dimeric
structure [7]. Its peculiar quaternary structure, in which the
two subunits exchange their N-terminal helices is also impor-
tant for a full antitumor activity [8].
By protein engineering techniques, we were able to trans-
form RNase A, monomeric and devoid of the cytotoxic activ-
ity characteristic of BS-RNase, into an e¡ective antitumor
agent. This was accomplished [9,10] by substituting into its
polypeptide chain four residues with those present at the
same positions in BS-RNase: Pro, Leu, and two Cys, at posi-
tions 19, 28, 31, and 32, respectively. However, the antitumor
activity of this mutein of RNase A is only about 60% that of
native BS-RNase [9]. This indicates that other determinants
must exist that are absent in the dimeric mutant of RNase A
as constructed.
Recently, S. Benner and coworkers [11,12] have identi¢ed
the main determinants of the activity of BS-RNase on double-
stranded RNA. In particular, their results point to the impor-
tant role of the Gly residues at positions 38 and 111. These
residues are simultaneously present only in the subunit chain
of seminal RNase, and in no other member of the terrestrial
RNase superfamily ([13] and references therein).
Here we report that second generation dimeric mutants of
RNase A, which include the additional substitutions D38G
and E111G to the already known sequence determinants
P19, L28, Cys-31 and Cys-32, possess an increased antitumor
action, and that the full complement of the latter mutations is
necessary to obtain a mutant of RNase A with a cytotoxic
action as powerful as that of natural BS-RNase.
2. Materials and methods
2.1. DNA manipulations
Bacterial cultures, plasmid puri¢cations and transformations were
performed according to Sambrook et al. [14]. Double-stranded DNA
was sequenced with the dideoxy method of Sanger [15], carried out
with a Sequenase Sequencing Kit and labelled nucleotides from Amer-
sham. The cDNa coding for PLCC-RNase A was prepared as de-
scribed [9]. The mutations reported here were introduced in the
PLCC-RNase A cDNA following the methodology of Kunkel [16]
using mutagenic oligonucleotides synthesized at the Stazione Zoolog-
ica ‘A. Dohrn’ (Naples, Italy). The mutations were always veri¢ed by
DNA sequencing. E. coli strain JM101 was from Boehringer; plasmid
pET22b(+) and E. coli strain BL21(DE3) from AMS Biotechnology.
Enzymes and other reagents for DNA manipulation were from Prom-
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ega Biotech. Aeromonas proteolytica aminopeptidase was purchased
from Sigma.
2.2. Proteins
BS-RNase was puri¢ed from seminal vesicles as described by Tam-
burrini et al. [17].
The cloned cDNAs coding for the recombinant proteins, inserted
into the pET22b(+) expression vector, were expressed and puri¢ed
essentially as described previously [9,10]. Yields of dimers ranged
from 8 to 10 mg per liter of bacterial culture. The percentage of
MUM and M = M forms in dimeric mutant RNases was determined
as previously described [3].
2.3. Antitumor assays
Cytotoxicity of proteins was assayed as described [7] on SVT2 cells
(ATCC, Richmond, VA, USA), grown in Dulbecco’s modi¢ed Eagle’s
medium, supplemented with 10% FCS, 4 mM glutamine, 400 U/ml
penicillin and 0.1 mg/ml streptomycin. Cells were seeded in 24-well
plates (2.5U104/well) in the presence of the protein to be tested. Cell
survival, with respect to control cultures grown in the absence of the
protein, was measured in triplicate. Controls on the absence of cyto-
toxicity of the RNases under study on the parent non-transformed
3T3 cells were routinely run.
2.4. Kinetic assays
RNase activity on yeast RNA was assayed with the method of
Kunitz [18]. Poly(A)WPoly(U) was purchased from Sigma and used
as a substrate [19] for the RNase muteins in 100 mM MOPS, pH
7.5, containing 100 mM NaCl. The speci¢c activities were calculated
from the initial rates by measuring the slope of the linear parts of the
recordings, and were expressed as an increase in absorbance at 260 nm
per minute per mg of protein with 40 Wg/ml of Poly(A)WPoly(U) at
25‡C.
2.5. Other methods
SDS-PAGE was carried out according to Laemmli [20]. Protein
sequence determinations were performed on an Applied Biosystems
sequencer mod. 473A, connected on-line with the HPLC apparatus
for identi¢cation of phenylthiohydantoin derivatives. The electrospray
mass spectrometric analyses were performed on a VG Bio Q mass
spectrometer (VG Analytical) at CEINGE Biotecnologie Avanzate
(Naples, Italy).
3. Results and discussion
The antitumor activity of the mutant PLCC-RNase AA is
only about 60% that of native BS-RNase [9]. This mutant was
obtained [9,10] by replacing into RNase A polypeptide chain
the residues present at positions 19, 28, 31, and 32 with those
present at the same positions in the subunit of BS-RNase:
Pro, Leu, and two Cys, respectively.
We have previously demonstrated [21] that full antitumor
action of recombinant seminal RNase depends on the removal
of its N-terminal unprocessed methionine. Although neither
crystallographic nor biological data point out any speci¢c role
of the N-terminal residue of the polypeptide chain of BS-
RNase, we ¢rst explored the possibility that the methionine
residue present at the N-terminal of the mutant PLCC-RNase
AA could impair the full antitumor activity of the mutant. We
thus removed the (31) methionine of the recombinant PLCC-
RNase AA, and assayed the mature protein for its cytotoxic
activity. The results of the assays (data not shown) indicated
that the removal of the N-terminal methionine does not a¡ect
the antitumor action of PLCC-RNase AA.
Thus we turned our attention to another of the features
essential for the antitumor action of BS-RNase: its catalytic
activity as a ribonuclease [7]. The comparison of RNase A,
inactive as cytotoxic agent, and BS-RNase, endowed with
speci¢c cytotoxicity towards tumor cells, with respect to their
catalytic activity, has revealed that BS-RNase possesses cata-
lytic activity towards double-stranded RNA [5], which is ab-
sent in RNase A assayed under the same conditions [5]. Re-
cently, Benner and coworkers [22] have given evidence that
Gly-111 and Gly-38 in BS-RNase account for the enhanced
action of the enzyme against duplex nucleic acid structures.
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Table 1
Catalytic activity and MUM content of the mutants of RNase A
Protein MUM (%) at time 0 MUM (%) at 96 h ssRNAa Poly(A)WPoly(U)
RNase A 100 þ 2 1.2 þ 0.1
PLCC-RNase AA 16 þ 1 71 þ 1 78 þ 4 3.50 þ 0.15
PLCC(G38)-RNase AA 58 þ 1 71 þ 1 75 þ 3 35 þ 3
PLCC(G111)-RNase AA 13 þ 1 70 þ 1 75 þ 4 8.0 þ 0.5
PLCCGG-RNase AA 62 þ 1 69 þ 1 54 þ 4 33 þ 2
BS-RNase 70 þ 2 70 þ 2 42.0 þ 1.5 11 þ 1
aRelative to RNase A speci¢c activity, taken as 100. The activity of RNase A ranged between 99 and 113 Kunitz units/mg of protein.
Fig. 1. Survival of malignant ¢broblasts grown in the presence of
(R) RNase A, (a) BS-RNase, (O) PLCC-RNase AA, (E)
PLCC(G38)-RNase AA, (F) PLCC(G111)-RNase AA, and (b)
PLCCGG-RNase AA. A: Survival of cells grown in the presence of
50 Wg/ml of each RNase; B: dose response curve determined after
48 h of growth.
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Thus, given the ¢nal target in the mechanism of the antitumor
action of BS-RNase [6], i.e. ribosomal RNA, we prepared
second generation dimeric mutants of RNase A which in-
cluded, besides the already known sequence determinants
P19, L28, Cys-31 and Cys-32, the additional substitutions
D38G and E111G, in various combinations.
The mutant cDNAs, obtained as described in Section 2,
were expressed in Escherichia coli as described previously for
the mutant PLCC-RNase AA [10]. Brie£y, the muteins, all
found only in inclusion bodies, were ¢rst totally reduced
and unfolded, and then refolded in the presence of a gluta-
thione redox bu¡er into catalytically active monomers, linked
through mixed disul¢des with two glutathione moieties. The
protecting glutathione moieties were then removed by mild
reduction, followed by dialysis. Under these conditions, the
monomers associated into homogeneous dimers linked by in-
tersubunit disul¢des, as indicated by SDS-PAGE analyses run
under non-reducing and reducing conditions (data not
shown). The muteins were also characterized by N-terminal
sequencing, and by electrospray mass spectrometric analyses
of their molecular weights.
Given the dependence of the antitumor activity of BS-
RNase [8], and of the dimeric mutants of RNase A [10] on
their quaternary conformation, i.e. on the presence of
the more active MUM forms, we ¢rst measured the exchang-
ing dimer content of the preparations of the mutants
PLCC(G38)-, PLCC(G111)-, and PLCCGG-RNase AA (see
Table 1), and then incubated each mutant for 96 h under
conditions that induce the transformation of the M = M
form into MUM.
Data in Table 1 show that at equilibrium the MUM con-
tent of all the mutants is similar to that of natural BS-RNase,
and to that of parent PLCC-RNase AA. Thus, it seems that
mutations D38G and E111G do not alter the thermodynamic
barrier between non-exchanged (M = M) and exchanged
(MUM) dimers. A further indication can be derived from
the data collected measuring the MUM content of each pro-
tein preparation just after its puri¢cation. It is evident from
the data in Table 1 that the content in the exchanging forms
of both mutants harboring mutations D38G is much higher
than that of the other mutant, almost approaching the equi-
librium value. This would indicate a greater kinetic propensity
of these mutants to displace the N-terminal helix from the
body of one subunit to the other, which might depend either
on the loss of a negative charge at position 38 (glycine repla-
ces an aspartic acid residue at this position in both mutants)
and/or on the loss of a bulky side chain, which is in the
contact region between the exchanged N-terminal helix and
the body of the other subunit [4].
The selective cytotoxic e¡ect of these mutated ribonucleases
was tested by measuring the percent of survival of SVT2 ¢-
broblasts as derived from growth curves obtained in the ab-
sence or in the presence of 50 Wg/ml of the proteins under test,
and from a dose-response experiment (Fig. 1).
All dimeric mutants displayed a strong cytotoxic e¡ect. The
data lead to the conclusion that while wild-type RNase A has
no e¡ect on cell growth, and the antitumor e¡ect of PLCC-
RNase AA is about 60% of that of natural BS-RNase, the
introduction of a glycine residue either at position 38 or at
position 111 into PLCC-RNase AA polypeptide chain in-
creases the antitumor action of the corresponding mutant,
with respect to the parent protein. This e¡ect is additive as
the mutant with both glycine residues at positions 38 and 111
displays a cytotoxic e¡ect, in fact as powerful as that of nat-
ural BS-RNase.
Benner and coworkers have recently found [22] that the
ability of dimeric mutants of RNase A to cleave dsRNA de-
pends on the presence of residues G38 and G111. They have
also shown [12] that dimeric RNases joined by disul¢de
bridges between Cys residues 31 and 32 of both subunits,
can be linked through a ‘parallel connectivity’ with Cys-31
and Cys-32 of one subunit linked with Cys-31P and Cys-32P,
respectively, of the other subunit, or by an ‘antiparallel con-
nectivity’, with Cys-31 and Cys-32 of one subunit linked with
Cys-32P and Cys-31P, respectively, of the other subunit. In
turn, the kind of connectivity in£uences the ability of the
dimers to exchange their N-terminal helices, the dimers being
linked through a ‘parallel connectivity’ impaired to displace
their N-terminal segments [12].
We also assayed our mutants, di¡ering from those used by
Benner and coworkers, for having residue P19, for their abil-
ity to cleave single- and double-stranded structures.
The data reported in Table 1 show that the dimeric mutant
PLCC-RNase AA, which includes all the determinants known
to contribute to the dimeric structure and to the exchange
properties of BS-RNase, has a reduced activity on single-
stranded RNA with respect to parent monomeric RNase A,
as it is typical of dimeric RNases, and an enhanced action,
3 times higher, on double-stranded RNA, with respect to
monomeric RNase A. Also the glycine residue at position
111 contributes to the activity on dsRNA, as the activity of
mutant PLCC(G111)-RNase AA is about 8 times higher, with
respect to pancreatic RNase A. But the main contribution to
the capability of degrading double-stranded substrates is given
by glycine 38. In fact, mutant PLCC(G38)-RNase AA shows
a 28-fold increase in the activity towards dsRNA, con¢rming
the data reported by Opitz et al., although the activity values
reported in the present paper are lower than those reported by
Opitz [22]. These di¡erences are most probably due to the
lower ionic strength in our assay mixture. Moreover, it would
seem that the contribution of residue G111 is rather marginal,
as mutant PLCCGG-RNase AA displays an increase in the
activity with respect to RNase A, almost identical to that of
PLCC(G38)-RNase AA. It should also be noted that the ac-
tivity of the double mutant on single-stranded RNA is more
similar to that of BS-RNase, when compared to that of the
other mutants. Thus, the data reported in the present paper,
in agreement with those reported by Opitz [22], would indicate
a key role of the residue present at position 38 in determining
the strong increase in the catalytic activity of the dimeric
mutants of RNase A on dsRNA, with respect to the parent
protein. These results are in line with the proposal of Sorren-
tino et al. that the destabilization of polynucleotide secondary
structures by RNases depends on the localization of a high
positive charge density in discrete regions of the molecule,
rather than on the global net positive charge of the molecule
[19]. Thus, the contribution of the residue present at position
38 of mutants of RNase A might be another determinant of
their high catalytic activity on dsRNA, besides the localized
presence of positive charge density on the surface of the mol-
ecule.
Thus, our data indicate that the cytotoxic activity of the
mutants of RNase does not seem to be related to the ability of
the same mutants to degrade dsRNA. While both mutations
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at positions 38 and 111, with a Gly residue replacing Asp and
Glu, respectively, seem equally essential to the full display of
antitumor action, the main contribution to the activity on
dsRNA seems to derive from the presence of a Gly residue
at position 38. Thus, a linear correlation between the activity
on double-stranded RNA of the mutants of pancreatic RNase
A harboring mutations D38G and E111G, and their cytotoxic
activity cannot be made. However, the interplay between the
presence of Gly residues at positions 38 and 111, and the
connectivity between the dimers, and hence their tendency
to exchange their N-terminal helices, could be the cause of
the enhanced antitumor activity of the mutants carrying those
residues. Alternatively, it could be hypothesized that the re-
moval of two negative charges, that of aspartate 38 and glu-
tamate 111, might favor the binding of the muteins to the
extracellular matrix, and/or their transfer to cytosol through
membranes. Both events have been implicated in the mecha-
nism of the antitumor action of BS-RNase [6,23].
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